“As an active angel investor and member of the Investor Advisory Board, I appreciate the opportunity to work with the Institute which is an integral part of Florida's strategy to build a knowledge-based economy. The organization provides much needed support to public research institutions, helping them to create the entrepreneurial infrastructure necessary for Florida to compete on the global stage.” Neil McFarlane, McFarlane BioVentures
“The Florida Patent Pro Bono Program has worked aggressively to match me with a reputable law firm to prosecute my patent.  Their hands-on approach and obvious commitment to service gives you relief, a better understanding for the process, and the procedures that follow.  To my benefit, I put my trust in what they had to offer and soon found out that I did the right thing by contacting them. Thanks FloBono!” -Gary Souders, Inventor
“I have recently had the privilege to serve on a Governor's appointed strategic planning committee to develop a technology based economic development strategy in Alabama, and I applaud Florida's efforts, through the Institute, to increase the role of universities in new company creation and job growth. With a research base as large as Florida's, there is tremendous opportunity to create the companies whose products and services will improve our quality of life while building an economic development engine that will create high quality jobs and capital investment in Florida, now and in the decades to come. “ Robert L. Crutchfield, Venture Partner, Harbert Venture Partners
 “Florida has become a leader in the global life sciences industry. In support of this achievement, the Florida Institute for the Commercialization of Public Research is one of our most valuable assets. It focuses on a long term economic development strategy and provides the highest level of experience, innovative programs and private sector partners to generate positive economic and social impact. Without the Institute, GLG Pharma would not be where we are today, raising money, hiring associates, and actively working to commercialize a technology that originated at the H. Lee Moffitt Cancer Center that will result in the next generation of personalized therapies for the treatment of cancer.” Michael Lovell, PhD, President, GLG Pharma


Facebook icon
Twitter icon
LinkedIn icon
Pinterest icon
e-mail icon